

Operating Results for Fiscal 2005 of Individual Member Companies (Consolidated)																						
(Comparative table of sales and income)																						
Table 2-1 The total of the top 14 members recorded more than 100 billion yen in sales																						
Unit: million yen																						
Name of Company	Closing date	Sales			Operating income			Ordinary income			Net Income			Prospects for FY2006								
		FY2004	Change		FY2004	Change		Ratio to sales	FY2004	Change		Ratio to sales	FY2004	Change		Ratio to sales	Sales		Ordinary Income		Net Income	
		FY2005	Amount	%	FY2005	Amount	(%)	(%)	FY2005	Amount	(%)	(%)	FY2005	Amount	(%)	(%)	FY2006	Change from FY2005	FY2006	Change from FY2005	FY2006	Change from FY2005
		1,122,960			385,278		34.3	442,111			39.4	277,438			24.7	1.5%		0.1%		2.2%		
Takeda Pharmaceutical Company Limited	End of Mar.	1,212,207	89,247	7.9	402,809	17,531	4.6	33.2	485,354	43,243	9.8	40.0	313,249	35,811	12.9	25.8	1,230,000	17,793	486,000	646	320,000	6,751
		862,010			192,238		22.3	194,235			22.5	59,532			6.9	2.6%		-9.2%		18.7%		
Astellas Pharma Inc.	End of Mar.	879,361	17,351	2.0	193,020	782	0.4	22.0	202,588	8,353	4.3	23.0	103,658	44,126	74.1	11.8	902,000	22,639	184,000	-18,588	123,000	19,342
		533,011			86,807		16.3	89,087			16.7	55,505			10.4	6.4%		4.0%		5.7%		
Eisai Co., Ltd.	End of Mar.	601,252	68,241	12.8	95,704	8,897	10.2	15.9	100,025	10,938	12.3	16.6	63,410	7,905	14.2	10.5	640,000		104,000	3,975	67,000	3,590
		587,830			84,925		14.4	82,506			14.0	48,282			8.2	-6.6		-28.2%		-46.6%		
Sankyo Co., Ltd.	End of Mar.	579,949	-7,881	-1.3	78,335	-6,590	-7.8	13.5	82,164	-342	-0.4	14.2	50,627	2,345	4.9	8.7	865,000	-61,396	115,000	-45,093	47,000	-41,036
		328,534			56,063		17.1	57,320			17.4	37,175			11.3							
Daiichi Pharmaceutical Co., Ltd.	End of Mar.	346,447	17,913	5.5	76,087	20,024	35.7	22.0	77,929	20,609	36.0	22.5	37,409	234	0.6	10.8						
		294,670			51,497		17.5	51,990			17.6	34,117			11.6	-4.3%		-33.7%		-40.7%		
Chugai Pharmaceutical Co., Ltd.	End of Dec.	327,155	32,485	11.0	79,168	27,671	53.7	24.2	82,091	30,101	57.9	25.1	53,632	19,515	57.2	16.4	313,000	-14,155	54,400	-27,691	31,800	-21,832
		279,437			54,698		19.6	58,063			20.8	35,489			12.7	-2.0%		-8.5%		-23.4%		
Taisho Pharmaceutical Co., Ltd.	End of Mar.	271,407	-8,030	-2.9	46,395	-8,303	-15.2	17.1	49,748	-8,315	-14.3	18.3	35,884	395	1.1	13.2	266,000	-5,407	45,500	-4,248	27,500	-8,384
		230,003			47,107		20.5	47,125			20.5	27,134			11.8	8.1%		10.8%		3.8%		
Terumo Corporation	End of Mar.	247,048	17,045	7.4	48,251	1,144	2.4	19.5	48,934	1,809	3.8	19.8	32,457	5,323	19.6	13.1	267,000	19,952	54,200	5,266	33,700	1,243
		173,899			10,396		6.0	11,187			6.4	6,924			4.0	5.8%		46.9%		36.6%		
Dainippon Sumitomo Pharma Co., Ltd.	End of Mar.	245,783	71,884	41.3	28,885	18,489	177.8	11.8	27,235	16,048	143.5	11.1	15,377	8,453	122.1	6.3	260,000	14,217	40,000	12,765	21,000	5,623
		234,244			31,049		13.3	29,959			12.8	13,172			5.6	-0.0		-0.1%		-0.5%		
Mitsubishi Pharma Corporation	End of Mar.	236,207	1,963	0.8	36,235	5,186	16.7	15.3	36,020	6,061	20.2	15.2	20,699	7,527	57.1	8.8	236,200	-7	36,000	-20	20,600	-99
		199,364			28,729		14.4	27,804			13.9	18,941			9.5	6.9%		4.5%		-20.8%		
Shionogi & Co., Ltd.	End of Mar.	196,388	-2,976	-1.5	29,226	497	1.7	14.9	29,656	1,852	6.7	15.1	22,735	3,794	20.0	11.6	210,000	13,612	31,000	1,344	18,000	-4,735
		171,984			27,467		16.0	27,585			16.0	15,902			9.2	0.3%		4.8%		11.2%		
Tanabe Seiyaku Co., Ltd.	End of Mar.	171,552	-432	-0.3	27,568	101	0.4	16.1	27,107	-478	-1.7	15.8	15,466	-436	-2.7	9.0	172,000	448	28,400	1,293	17,200	1,734
		145,302			60,043		41.3	61,955			42.6	39,322			27.1	-3.0%		-5.0%		-2.9%		
Ono Pharmaceutical Co., Ltd.	End of Mar.	148,671	3,369	2.3	56,936	-3,107	-5.2	38.3	59,245	-2,710	-4.4	39.8	36,146	-3,176	-8.1	24.3	144,200	-4,471	56,300	-2,945	35,100	-1,046
		83,545			21,495		25.7	21,871			26.2	12,873			15.4	4.3%		5.1%		0.4%		
Hisamitsu Pharmaceutical Co., Inc.	End of Feb.	102,665	19,120	22.9	22,770	1,275	5.9	22.2	24,159	2,288	10.5	23.5	14,448	1,575	12.2	14.1	107,100	4,435	25,400	1,241	14,500	52
Top 14 Total		5,246,793			1,137,792		21.7	1,202,798			22.9	681,806			13.0	-0.5		-6.5%		-5.9%		
		5,566,092	319,299	6.1	1,221,389	83,597	7.3	21.9	1,332,255	129,457	10.8	23.9	815,197	133,391	19.6	14.6	5,612,500	-26,009	1,260,200	-87,027	776,400	-48,690
Total of 16 companies		781,582			87,100		11.1	85,869			11.0	53,867			6.9	3.7%		-8.2%		-3.2%		
		805,604	24,022	3.1	90,493	3,393	3.9	11.2	91,564	5,695	6.6	11.4	55,635	1,768	3.3	6.9	840,750	30,077	84,760	-7,546	53,990	-1,757
Grand Total of 30 Companies		6,028,375			1,224,892		20.3	1,288,667			21.4	735,673			12.2	0.1%		-6.6%		-5.7%		
		6,371,696	343,321	5.7	1,311,882	86,990	7.1	20.6	1,423,819	135,152	10.5	22.3	870,832	135,159	18.4	13.7	6,453,250	4,068	1,344,960	-94,573	830,390	-50,447

Notes:

1.The order of listing up is in the order of those with the largest to the smallest amount of sales in FY2005

2.Figures and ratios in the above table are given in units of one million yen. Accordingly, they may differ from those publicized by each company

3.Data for Astellas Pharma Inc. are compared with the total sum of Yamanouchi and Fujisawa in FY2005.

4. Data for Nikken Chemicals and Torii Pharmaceutical is on non-consolidated basis, since neither company publishes consolidated financial statements.

5. Figures and ratios in "Prospect for FY2006" are given based on Table 1-2.

6. Prospects for the operating results of both Sankyo and Daiichi Pharmaceutical are based on those of Daiichi Sankyo, the holding company of both companies, and are compared with the total of the operating results for fiscal 2005 of both companies.

